# Xaira Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xaira-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.xaira.com/
- Total disclosed funding: $553M
- Latest round: Series A (Apr 17, 2024)
- Investors on record: 13

## About

Based in California, US, and founded in 2023 by Joe (Joe Watchwell) Watson, Buwei Huang, Nathaniel Bennett, and Philip Leung, Xaira Therapeutics, Inc. operates as a biotechnology company that provides advances in AI to transform how we treat disease. In April 2024, Xaira Therapeutics, Inc. raised USD 1 billion in venture funding co-led by investors Arch Venture Partners and Foresite Capitali, including F-Prime, New Enterprise Associates, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Investments, Parker Institute for Cancer Immunotherapy, Byers Capital, rSquared CRE, LLC, and SV Angel. As of 2024, the company is led by its CEO, Marc Tessier-Lavigne.

The company offers an AI platform designed to streamline the drug discovery process. Xaira's advanced generative AI is used for image generation to design molecular structures for drugs. The firm operates across three core areas: machine learning research to deepen biological insights, data generation to power advanced models, and therapeutic product development. The company focused on creating treatments that address a wide range of medical conditions, aiming to enhance patient outcomes and transform healthcare through technology-driven solutions.

## Funding rounds

- Series A, Apr 17, 2024, $553M — ARCH Venture Partners, Lightspeed Venture Partners, Menlo Ventures, New Enterprise Associates, Hong Shan, F-Prime Capital, Two Sigma Investments, Lux Capital, SV Angel, Foresite Capital, Parker Institute for Cancer Immunotherapy, Byers Capital, Rsquared VC
- Seed, Feb 1, 2024 — Lightspeed Venture Partners, Menlo Ventures, New Enterprise Associates

## Investors

- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Seed, Series A
- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Seed, Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Seed, Series A
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Hong Shan — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Two Sigma Investments (https://capitalatlas.ai/funds/two-sigma-investments) — Series A
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series A
- SV Angel (https://capitalatlas.ai/funds/sv-angel) — Series A
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A
- Parker Institute for Cancer Immunotherapy — Series A
- Byers Capital (https://capitalatlas.ai/funds/byers-capital) — Series A
- Rsquared VC (https://capitalatlas.ai/funds/rsquared-vc) — Series A